4.7 Letter

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy

Journal

CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 71, Issue 7, Pages 1777-1786

Publisher

SPRINGER
DOI: 10.1007/s00262-021-03104-1

Keywords

Immunotherapy; Cancer vaccines; Checkpoint blockade agents; Adoptive immunotherapy; Targeted therapies; NIBIT

Funding

  1. Bristol-Meyers Squibb
  2. Novartis
  3. Roche
  4. Akoya
  5. AstraZeneca
  6. Codiak
  7. Gilead
  8. Idera
  9. Immunocore
  10. Incyte
  11. Merk Sharp Dome (MSD)
  12. Pfizer Oncology
  13. Amgen
  14. Astellas
  15. Becton Dikinson (BD)
  16. Igea clinical Biophisics
  17. Ivitech
  18. Janssen oncology
  19. Merck
  20. Pierre Fabre Oncology
  21. Assing
  22. EuroClone
  23. Fuidigm
  24. PerkinElmer
  25. Werfen
  26. ACC
  27. AIOM
  28. SIC
  29. SIICA
  30. Associazione Italiana Oncologia Toracica (AIOT)
  31. Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC)
  32. Comune di Verona
  33. Universita di Verona
  34. Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri
  35. Fondazione Grazia Focacci
  36. Fondazione Italiana per la Ricerca sulle Malattie del Pancreas
  37. Fondazione Pezcoller
  38. Fondazione Melanoma Onlus
  39. Fondazione IRCCS Istituto Nazionale dei Tumori
  40. Istituto Oncologico Veneto (IOV)
  41. Women for Oncology Italy

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available